AVTX
Avalo Therapeutics, Inc. · Healthcare · Market cap $399.5M
Insiders sold $2.1M net in the last 90 days ·3 sellers, 0 buyers· 10 of 11 sales under Rule 10b5-1 plans· latest Form 4 filed Sep 18, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$8.5M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Latest filing
Sep 18, 2026
Sullivan Christopher Ryan
Avalo Therapeutics, Inc. (AVTX) has 43 SEC Form 4 filings (92 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Sep 18, 2026.
Inside the rolling window, 6 insiders at Avalo Therapeutics, Inc. reported no open-market purchases and 27 open-market sales totaling $8.5M. The most active filer is Chief Medical Officer Doyle Mittie with 13 filings. Insiders have net sold $7.9M over the trailing 6 months. The most recent open-market filing is a sale of 12,394 shares by Chief Financial Officer Sullivan Christopher Ryan, dated Sep 16, 2026, worth $202K.
- Industry:Biotechnology
- CEO:Garry A. Neil
- Employees:33
- HQ:Wayne, PA, US
- IPO:2015-10-14
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Financial Officer | Sale | 12,394 | $202K | Sep 18 | -55.0% | SEC ↗ | |
| Chief Financial Officer | Sale | 10,185 | $179K | Sep 11 | -53.8% | SEC ↗ | |
| Chief Medical Officer | Sale | 679 | $14K | Sep 1 | -60.7% | SEC ↗ | |
Sullivan Christopher RyanFirst in 3 months | Chief Financial Officer | Sale | 41,694 | $828K | Aug 19 | -64.1% | SEC ↗ |
Sullivan Christopher RyanFirst in 3 months | Chief Financial Officer | Sale | 31,031 | $622K | Aug 19 | -64.1% | SEC ↗ |
| Chief Medical Officer | Sale | 1,000 | $20K | Aug 19 | -64.1% | SEC ↗ | |
Riley JenniferFirst filing | Chief Strategy Officer | Sale | 2,655 | $52K | Aug 12 | -61.9% | SEC ↗ |
| Chief Medical Officer | Sale | 679 | $14K | Aug 12 | -61.9% | SEC ↗ | |
| Chief Medical Officer | Sale | 1,000 | $20K | Jul 29 | -60.8% | SEC ↗ | |
| Chief Medical Officer | Sale | 4,654 | $93K | Jul 2 | — | SEC ↗ | |
| Chief Medical Officer | Sale | 1,450 | $26K | Jun 25 | — | SEC ↗ | |
| Chief Medical Officer | Sale | 679 | $11K | Jun 1 | — | SEC ↗ | |
| Chief Medical Officer | Sale | 3,000 | $56K | May 19 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 18,606 | $449K | May 11 | — | SEC ↗ | |
| Chief Medical Officer | Sale | 1,679 | $27K | May 7 | — | SEC ↗ | |
| Chief Medical Officer | Sale | 106,555 | $2.2M | May 7 | — | SEC ↗ | |
VARKI PAULFirst filing | Chief Legal Officer | Sale | 75,063 | $1.5M | May 7 | — | SEC ↗ |
| Chief Financial Officer | Sale | 47,000 | $949K | May 7 | — | SEC ↗ | |
Chan MitchellFirst filing | Director | Sale | 3,167 | $72K | May 7 | — | SEC ↗ |
| Chief Financial Officer | Sale | 8,458 | $111K | May 1 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 8,457 | $112K | May 1 | — | SEC ↗ | |
| Chief Medical Officer | Sale | 3,970 | $72K | Apr 8 | — | SEC ↗ | |
Sullivan Christopher RyanFirst filing | Chief Financial Officer | Sale | 7,979 | $134K | Apr 3 | — | SEC ↗ |
Sullivan Christopher RyanFirst filing | Chief Financial Officer | Sale | 7,980 | $137K | Apr 3 | — | SEC ↗ |
| Chief Medical Officer | Sale | 679 | $11K | Apr 3 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does AVTX have?
Avalo Therapeutics, Inc. (AVTX) has 43 SEC Form 4 filings (92 transaction rows) in the rolling 365-day window, disclosed by 6 distinct insiders. Most recent filing: Sep 18, 2026.
When was the most recent SEC Form 4 filing for AVTX?
The most recent Form 4 filing for AVTX on Tracefour is dated Sep 18, 2026.
Who is the most active insider at AVTX?
The most active SEC Form 4 filer at AVTX in the rolling window is Chief Medical Officer Doyle Mittie, with 13 filings.
What is the net insider flow at AVTX over the last 6 months?
Over the trailing 180 days, insiders at AVTX have net sold $7.9M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at AVTX in the current window?
Inside the rolling window, insiders at AVTX bought $0 and sold $8.5M based on SEC Form 4 filings.
Can I get alerts for AVTX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Avalo Therapeutics, Inc. (AVTX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Avalo Therapeutics, Inc. is in the Healthcare sector.